AAP
CRSP icon

Arax Advisory Partners’s CRISPR Therapeutics CRSP Stock Holding History

Arax Advisory Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$77.2K Buy
1,416
+1,008
+247% +$53.1K ﹤0.01% 2925
2026
Q1 		$21.7K Buy
408
+52
+15% +$2.74K ﹤0.01% 2071
2025
Q4 		$18.7K Sell
356
-442
-55% -$26.5K ﹤0.01% 2151
2025
Q3 		$51.7K Buy
798
+780
+4,333% +$44.8K ﹤0.01% 1821
2025
Q2 		$876 Sell
18
-25
-58% -$967 ﹤0.01% 2818
2025
Q1 		$1.46K Buy
+43
New +$1.82K ﹤0.01% 2181
2022
Q4 		– Sell
-40
Closed -$3K – 1285
2022
Q3 		$3K Hold
40
– – ﹤0.01% 890
2022
Q2 		$2K Buy
+40
New +$2.35K ﹤0.01% 936

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arax Advisory Partners's CRSP Position: Q2 2026 in Review

Arax Advisory Partners increased its CRISPR Therapeutics (CRSP) stake by 247% in Q2 2026, buying an estimated $53.1K and bringing the position to 1,416 shares worth $77.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2925.

Arax Advisory Partners first reported a position in CRSP in Q2 2022 and has held it in 8 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Arax Advisory Partners held 1,416 shares of CRISPR Therapeutics worth $77.2K as of Q2 2026.
  • Arax Advisory Partners bought 1,008 CRISPR Therapeutics shares in Q2 2026, an estimated $53.1K.
  • CRISPR Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2925 holding.
  • Arax Advisory Partners first reported a position in CRISPR Therapeutics in Q2 2022 and has held it in 8 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.